TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

LYMZUL

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: US

Quick snapshot

LYMZUL

ST13

US500000097877503

Class

5

Filing

97877503

Registration

7637835

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

16

Latest update

07/11/2025

Classification

Registered

Trademark type

Word

Nice classes

5

Filing date

04/07/2023

Registration date

01/07/2025

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

01/07/2025

Last transaction

07/11/2025

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Foreign priority

Drawing code

4

Owner type

99

Owner location

Marseille, FR

Examiner

SINGER, MELANIE

Current location

FILE REPOSITORY (FRANCONIA)

Holders and representatives

Holders

PROVEPHARM LIFE SOLUTIONS

Representatives

Kaitlyn M. Garvin SAUNDERS & SILVERSTEIN LLP

Technical classification

Nice Classes

Class 5

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Pharmaceutical preparations for marking tissue by injection in surgery and internal medicine, for marking tissue of the digestive system by oral, anal or injectable administration, for oral and topical antiseptic treatment, for marking and functional verification of gynecological and urological systems by instillation, injection or local application; chemical preparations for medical use for marking tissue by injection in surgery and internal medicine, for marking tissue of the digestive system by oral, anal or injectable administration, for oral and topical antiseptic treatment, for marking and functional verification of gynecological and urological systems by instillation, injection or local application; injectable pharmaceutical solutions for use as a marker during gastrointestinal endoscopy; injectable pharmaceutical solutions used as a contrast solution for medical imaging procedures; injectable pharmaceutical solutions for medical diagnostic purposes for viewing and marking tissue; injectable pharmaceutical solutions used as an aid in visualization of topographic irregularities and in delineation of polypoid or flat lesions, including adenomas; injectable pharmaceutical solutions used for polyps or lesions resection medicines for tissue staining; injectable pharmaceutical solutions for use as a marker during visceral surgery; injectable pharmaceutical solutions for the detection of amniotic fluid leaks; injectable pharmaceutical solutions for use as a marker during cystoscopy and ureteral catheterization; injectable pharmaceutical solutions for use as a marker during vessel delineation and tumor localization procedures; clinical medical reagents; synthetic peptides for pharmaceutical use, namely, for cancer treatments, immunotherapy, cell therapy, antivirals and antibiotics; phytotherapy preparations for medical use; diagnostic preparations in vials for medical use; drug delivery agents in the form of injectable compounds being pharmaceutical solutions in pre-filled vials that facilitate the delivery of pharmaceutical preparations; pre-filled syringes for medical and clinical purposes, sold filled with injectable pharmaceutical solutions for marking tissue by injection application in surgery and internal medicine, for marking tissue of the digestive system by oral, anal or injectable, for the antiseptic treatment orally or topically, for marking and functional verification gynecological and urological systems, by instillation, injection or local application

Publications

History of USPTO decisions and trademark events.

16 publications found

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

01/07/2025

R.PR

REGISTERED-PRINCIPAL REGISTER

01/07/2025

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

09/17/2024

PUBO

PUBLISHED FOR OPPOSITION

09/17/2024

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

08/28/2024

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

08/12/2024

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

08/11/2024

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

08/11/2024

ALIE

ASSIGNED TO LIE

08/10/2024

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

02/23/2024

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

01/16/2024

GNRT

NON-FINAL ACTION E-MAILED

01/16/2024

CNRT

NON-FINAL ACTION WRITTEN

01/16/2024

DOCK

ASSIGNED TO EXAMINER

01/04/2024

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

05/02/2023

NWAP

NEW APPLICATION ENTERED

04/11/2023

Continuous trademark protection

Get notified about every new filing that threatens LYMZUL or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.